OR WAIT null SECS
April 14, 2025
Article
Bristol Myers Squibb says mavacamten missed dual primary endpoints in Phase 3 ODYSSEY-HCM trial for symptomatic non-obstructive HCM.
Video
Bhatt discusses his expectations for the future of cardiology in 2025, including GLP-1-RAs and the push towards combination therapy.
April 11, 2025
Ruff discusses his expectations for cardiology for the rest of 2025, including new research into GLP-1 receptor agonists.
April 10, 2025
Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.
April 09, 2025
Deepak Bhatt, MD, MPH, MBA, explores high-impact trials from ACC.25, including REVERSE-IT, Alpaca, ADVANCE-HTN, SOUL, STRIDE, and DapaTAVI.
Podcast
In this episode, hosts break down the STRIDE and SOUL trials presented at the American College of Cardiology 2025 Annual Scientific Sessions.
April 08, 2025
Our Q1 2025 recap for cardiology spotlights 6 regulatory updates, 5 key trial announcements, and top expert perspectives in cardiac care.
April 03, 2025
A recap of 10 clinical trials in cardiovascular care to know from the American College of Cardiology 2025 Scientific Sessions.
April 02, 2025
Le examines the STRIDE, SOUL, and DapaTAVI trials presented at this year’s ACC Scientific Sessions.
April 01, 2025
At ACC.25, Boer highlights treatment gaps in the US for lipid control in a high-risk ASCVD population.
